Remuneration, KPI's, STI's, LTI's, page-54

I would think all of the KPI's will be met with the exception of the last (time will tell)

There is a very low threshold in my opinion
So CEO will receive the performance shares if not voted down by shareholders

However if voted down the remuneration committee will find alternative ways to pay our CEO

Currently there are about 16 million shares in register that owners of have indicated will vote no to remuneration package

Hopefully the fund managers will come on board.........not holding my breath though

JULY 2021-JULY 2022

Deferred STI Equity Performance Conditions - Key
Strategic Objectives – 1 year performance period

FOR JACKIE FAIRLEY


The vesting of the Deferred STI Equity is dependent
upon the extent to which the STI Corporate KPIs set by
the non-executive Directors have been achieved over
the Deferred STI Equity Performance Period.


STI Corporate KPIs

Viraleze™ and SPL7013 other uses
Continue roll-out of Viraleze® and further development
activities to support marketing and commercialisation.

THIS WILL BE MET

VivaGel® BV and associated products
Maximise the value of products through:
• diligent regulatory activities to secure additional
approvals; and
• working effectively with commercial partners and
suppliers to facilitate timely launch of the product in
multiple markets.

THIS WILL BE MET

DEP®
Maximise the value of the DEP® platform technology by:
• supporting and further developing existing DEP®
partnerships (e.g. AstraZeneca and Merck & Co.,
Inc.,);
• securing new DEP® partnering deals/licences;
• progressing internal clinical DEP® programs into and
through clinical development (or signing a licence, as
appropriate) with a focus on expediting outcomes and
building value which may be through additional
indications and/or combinations; and
• advancing additional internal DEP® product
candidates through preclinical development (or
signing a licence or other commercial arrangement,
as appropriate).

THIS WILL BE MET

Capital management and people
• Manage the Company’s finances in a prudent manner
to:
o create value; and
o increase recurrent revenues.
• Maintain and develop:
o a highly results oriented culture;
o exceptional leadership; and
o organisational development,
to achieve superior performance.

NOT SURE ABOUT THIS BEING MET